Normal view MARC view ISBD view

Two - vs three - drug combination chemotherapy in advanced or recurrent head and neck cancer: a single institution experience of 361 patients.

In Medical Oncology
Contributor(s): DCruz AK | Pathak KA | Mistry RC | Parikh PM | Parikh DM | Bakshi AV | Deshmukh C | Mazumdar, AT | drvrpai@rediffmail.com | Pai VR.
Material type: materialTypeLabelArticleSeries: Vol 21 Issues 4.Publisher: 2004Description: 305-308.Subject(s): Head and Neck cancer, Ifosfamide, Taxanes, Head cancer, Neck cancer, Chemotherapy, Three-drug combination, India | DDC classification: In: Medical OncologySummary: Head and Neck squamous cancer is a major concern in India. The proportion of advanced cases is significantly high, and these patients have dismal survival prospects aggresive therapy. Often surgical resection and /or radiotheapy are not feasible in these patients. Hence, we decided to explore the options of neoadjuvant chemotherapy using effective agents like ifosfamide and paclitaxel in combination with cisplatin in these patients. A total of 361 patients were evaluable at the end of study. Of these, 207 had received ifosfamide and cisplatin and 154 had recevied taxanes (paclitaxel or docetaxel) in addition to ifosfamide and cisplatin. The ifosfamide-cisplatin group had an overall resposne rate of 66.67% (CR, 16.42%, PR, 50.24%) and the median duration of response was 5.5 mo; whereas the group in which taxanes were added, showed an overall reponse rate of 73.37% (CR, 7.79%; PR, 65.58%) with a median duration of response of 10 mo. The toxicity in both groups was acceptable and there was no mortality. We c
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR4947

Head and Neck squamous cancer is a major concern in India. The proportion of advanced cases is significantly high, and these patients have dismal survival prospects aggresive therapy. Often surgical resection and /or radiotheapy are not feasible in these patients. Hence, we decided to explore the options of neoadjuvant chemotherapy using effective agents like ifosfamide and paclitaxel in combination with cisplatin in these patients. A total of 361 patients were evaluable at the end of study. Of these, 207 had received ifosfamide and cisplatin and 154 had recevied taxanes (paclitaxel or docetaxel) in addition to ifosfamide and cisplatin. The ifosfamide-cisplatin group had an overall resposne rate of 66.67% (CR, 16.42%, PR, 50.24%) and the median duration of response was 5.5 mo; whereas the group in which taxanes were added, showed an overall reponse rate of 73.37% (CR, 7.79%; PR, 65.58%) with a median duration of response of 10 mo. The toxicity in both groups was acceptable and there was no mortality. We c

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha